SAMHSA extends methadone take-home flexibilities initiated during pandemic
The Substance Abuse and Mental Health Services Administration yesterday extended certain methadone take-home flexibilities for opioid treatment programs until one year after the end of the COVID-19 public health emergency, and said it is considering ways to make the flexibilities permanent.
SAMHSA in 2020 allowed states to request a blanket exception to allow stable patients in an opioid treatment program to receive 28 days of take-home doses of their OUD medication, and other eligible patients to receive up to 14 days of take-home medication, which the agency said has enhanced and encouraged use of treatment services.
Related News Articles
Headline
The latest estimates on overdose deaths released yesterday by the Centers for Disease Control and Prevention show that as of August 2025, deaths fell…
Headline
A Centers for Disease Control and Prevention report found a drastic increase in alcohol-related emergency department visits from 2003-2004 to 2021-2022. The…
Headline
President Trump Dec. 1 signed the AHA-supported SUPPORT Act (H.R. 2483) into law. The legislation reauthorizes key prevention, treatment and recovery programs…
Headline
A Health Affairs study published Nov. 3 examined an increase in states banning prior authorizations in private insurance plans for opioid use disorder…
Perspective
More than 48 million Americans — 16.8% of the 12-and-older population — have a substance use disorder (SUD), according to the 2025 National Survey on Drug Use…
Headline
HHS awards $1.5 billion in opioid response grants to states, tribal communities The Department of Health and Human Services announced yesterday that it…